Sanofi added hepatitis B vaccine and a shingles clinical candidate to its vaccine portfolio through the acquisition of select Dynavax assets, the companies reported. The deal broadens Sanofi’s immunization offerings and strengthens its viral vaccine pipeline ahead of expected demand shifts in global markets. For Dynavax, the transaction represents a strategic divestment of late‑stage and commercial vaccine assets; for Sanofi, it provides near‑term product and candidate synergies with established immunization infrastructure. The transfer will likely influence competitive dynamics in prophylactic vaccines and spur integration work around manufacturing, regulatory filings and global launch planning.